Corrigendum to: "Naturally occurring interference in Luminex® assays for HLA-specific antibodies: Characteristics and resolution" [Hum. Immunol. 70 (2009) 496-501] (DOI:10.1016/j.humimm.2009.04.001);Naturally occurring interference in Luminex® assays for HLA-specific antibodies: Characteristics and resolution

Human Immunology

Volumn 70, Issue 7, 2009, Pages 496-501

  Zachary, Andrea A ^a   Lucas, Donna P ^a   Detrick, Barbara ^a   Leffell, Mary S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody testing; Crossmatch testing; Nonspecific reactivity

Indexed keywords

ANTIBODY; DITHIOTHREITOL; HLA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ACCURACY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD GROUP TYPING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FRACTIONATION; HUMAN; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE;

ANTIBODIES; ANTIBODY SPECIFICITY; DIALYSIS; DITHIOTHREITOL; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; HYPOTONIC SOLUTIONS; IMMUNOASSAY; ISOTONIC SOLUTIONS; REPRODUCIBILITY OF RESULTS; TISSUE TRANSPLANTATION;

EID: 67449132108     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.07.008     Document Type: Erratum

References (21)

1. Hopkins K.A. The basic lymphocyte microcytotoxicity tests: Standard and AHG enhancement. In: Hahn A.B., Land G.A., and Strothman R.M. (Eds). The ASHI Laboratory Manual. 4th ed. (2000), The American Society for Histocompatibility and Immunogenetics, Mt. Laurel, NJ 1.C.1.1-1.5
2. Zachary A.A., and Leffell M.S. Detecting and monitoring human leukocyte antigen-specific antibodies. Human Immunol 69 (2008) 591-604
3. Kao K.J., Scornik J.C., and Small S.J. Enzyme-linked immunoassay for HLA antibodies- An alternative to panel studies by lymphocytotoxicity. Transplantation 55 (1993) 192-196
4. Zachary A.A., Delaney N.L., Lucas D.P., and Leffell M.S. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets. I. Evaluation of the GTI QuikID assay and analysis of antibody patterns. Human Immunol 62 (2001) 228-235
5. El-Awar N., and Terasaki P.I. HLA antibody identification with single antigen beads compared to conventional methods. Human Immunol 66 (2005) 987-989
6. Jackson A.M., and Zachary A.A. The problem of transplanting the sensitized patient: Whose problem is it?. Front Biosci 13 (2008) 1396-1412
7. Gebel H.M., Harris S.B., Zibari G., and Bray R.A. Conundrums with Flow-PRA beads. Clinical Transplant 16 Suppl 7 (2002) 24-29
8. Espersen G.T., Ernst E., Vestergaard M., and Grunnet N. ELISA estimations of rheumatoid factor IgM, IgA, and IgG in sera from RA patients with high disease activity. DTT treatment studies. Scan J Rheumatol Suppl 75 (1988) 40-45
9. Hahn A.B. Inactivation of IgM antibodies: A. DTT treatment B. Heat inactivation. In: Hahn A.B., Land G.A., and Strothman R.M. (Eds). The ASHI Laboratory Manual. 4th ed. (2000), American Society for Histocompatibility and Immunogenetics, Mt. Laurel, NJ 1.B.4.1-4.4
10. Andrew S.M., Titus J.A., Coico R., and Amin A. Purification of Immunoglobulin M and Immunoglobulin D. Curr Protoc Immunol (2001) May; Chapter 2: Unit 2.9.
11. Zachary A.A., Montgomery R.A., and Leffell M.S. Defining unacceptable HLA antigens. Cur Opin Organ Transplant 13 (2008) 405-410
12. Leffell M.S., Montgomery R.A., and Zachary A.A. The changing role of antibody testing in transplantation. Clin Transpl (2005) 259-271
13. Bray R.A., Nolen J.D., Larsen C., et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 6 (2006) 2307-2315
14. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 85 (2008) 1046-1050
15. Reinsmoen N.L., Lai C.-H., Vo A., Cao K., Ong G., Naim M., et al. Acceptable donor specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86 (2008) 820-825
16. Tambur A.R., Leventhal J., Kaufman D.B., et al. Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: The Northwestern University experience. Transplantation 86 (2008) 1052-1059
17. Bingaman A.W., Murphey C.L., Palma-Vargas J., and Wright F. A vitual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 86 (2008) 1864-1868
18. Bielmann D., Honger G., Lutz D., et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 7 (2007) 626-632
19. th International HLA and Immunogenetics Workshop: Report on understanding antibodies in transplantation. Tissue Antigens 69 (2007) 160-173
20. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation 70 (2000) 887-895
21. Appel III J.Z., Hartwig M.G., Cantu III E., Palmer S.M., Reinsmoen N.L., and Davis R.D. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipient with HLA-specific antibodies. Transplantation 81 (2006) 1049-1057